The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma

Forker, L., Gaunt, P., Sioletic, S. et al. (13 more authors) (2018) The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma. British Journal of Cancer, 118 (5). pp. 698-704. ISSN 0007-0920

Abstract

Metadata

Authors/Creators:
  • Forker, L.
  • Gaunt, P.
  • Sioletic, S.
  • Shenjere, P.
  • Potter, R.
  • Roberts, D.
  • Irlam, J.
  • Valentine, H.
  • Hughes, D.
  • Hughes, A.
  • Billingham, L.
  • Grimer, R.
  • Seddon, B.
  • Choudhury, A.
  • Robinson, M.
  • West, C.M.L.
Copyright, Publisher and Additional Information: ©The Author(s) 2017. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Keywords: Sarcoma; Tumour biomarkers
Dates:
  • Accepted: 7 November 2017
  • Published (online): 12 December 2017
  • Published: 6 March 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 03 Jan 2018 11:57
Last Modified: 14 Jul 2020 14:01
Published Version: https://doi.org/10.1038/bjc.2017.430
Status: Published
Publisher: Cancer Research UK
Refereed: Yes
Identification Number: https://doi.org/10.1038/bjc.2017.430
Related URLs:

Download

Share / Export

Statistics